The five peptides everyone starts with

What people using it report

• As with tirzepatide, a large share of discussion is simply people working out that two differently branded products are the same molecule approved for different things at very different prices, and that a third similar drug is a different molecule again.
• The effect people describe valuing most is appetite and food preoccupation falling away rather than the number on the scale, and it is frequently described in terms of no longer having to spend attention on food.
• Direct comparison against tirzepatide is constant and goes both ways. A recurring pattern is people describing themselves as doing better on one than the other with no clear reason, and switching between them.

The full account, including the negative reports

What people using it report

• Almost never discussed alone. The overwhelmingly common pattern is pairing it with a growth hormone releasing hormone analogue, most often CJC-1295, which means essentially no self-report about it isolates this peptide from the other one.
• Doses people describe run around 200 to 300 mcg at night, sometimes split across the day, on schedules of five days on and two off. Those schedules come from forum convention rather than from any published human dosing.
• What people report wanting from it is recovery, sleep and body recomposition rather than weight loss, and experienced users repeatedly tell newcomers that it will not produce fat loss and that a GLP-1 drug is what does that.

The full account, including the negative reports

What people using it report

• Dose patterns described in circulation cluster around 250 to 500 mcg subcutaneously once or twice daily for four to eight weeks, often injected near the injured site. The strengths compounders proposed to FDA match that: 250 mcg, 500 mcg and 1 mg capsules and a 2,000 mcg/mL injection. Published clinic use looks different again, with single doses of 2 to 4 mg into a joint or 10 mg into the bladder wall.
• The injuries people describe treating are tendinopathy, especially elbow, shoulder and Achilles, partial muscle tears, knee pain and post-surgical recovery, plus gut complaints such as reflux and inflammatory bowel symptoms.
• Reported timelines are typically a reduction in pain in the first one to two weeks and a change in what the joint or tendon tolerates by weeks three to six. People who stop before about four weeks commonly report no lasting change.

The full account, including the negative reports

What people using it report

• TB-500 is most often described as part of a two-peptide protocol with BPC-157, sold and discussed as a healing or wolverine stack. Almost no self-report isolates it, so nothing people describe can be attributed to this peptide rather than the other one.
• Dosing patterns commonly described run as a loading phase of a few milligrams per week split into two injections for four to six weeks, followed by a lower maintenance dose. There is no published human dose, and reviews in the orthopaedic literature state plainly that indications, dose, frequency and duration are all undefined.
• The uses people report are chronic tendon and ligament complaints, shoulder and hip problems, scar tissue and range of motion, and general recovery between hard training blocks.

The full account, including the negative reports

What people using it report

• Split use. People apply it topically for skin and scalp, and inject it much less often. Topical is described by most as the sensible route, commonly mixed into water and sprayed or applied to scalp and face.
• Subcutaneous injection is described as genuinely unpleasant, with the injection site turning blue for two to three days and the injection itself reported as painful. That is the most consistent negative in the whole discussion and it is a reason people give for switching to topical.
• For hair, the repeated pattern is that nothing visible happens in the first four weeks and that people who report satisfaction are those who ran it six months alongside minoxidil and microneedling. Almost nobody reports it working alone.

The full account, including the negative reports